

## ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - TF Members and Additional Contributors

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Agewall Stefan	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Platelet inhibition
Alegria Ezquerro Eduardo	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Roche : dabigatran
Catapano Alberico	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : cardiovascular - Sanofi Aventis : cardiovascular - Genzyme, Shire HGT : cardiovascular - AstraZeneca : cardiovascular - Merck Schering Plough : cardiovascular D - Research funding (departmental or institutional). - Merck : basic research no direct link to products - AstraZeneca : epidemiology no direct link to products
Chapman John	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer Inc., New York : Autoimmune dyslipidemia - Merck : Cardiometabolic Disease - Roche Pharma : Cardiometabolic disease - Danone : Hypercholesterolemia D - Research funding (departmental or institutional). - Kowa : Dyslipidemia - Merck : None
De Backer Guy	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca - speaker fees : Crestor
Durrington Paul	No	
Erdine Serap	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Therapeutic Area - Daiichi Sankyo : Therapeutic Area - Novartis : Therapeutic Area

## ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - TF Members and Additional Contributors

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Erdine Serap	Yes	- Abbott Laboratories : Therapeutic Area
Graham Ian	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer - speakers fees : CVD risk B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - MSD - speaker fee : CVD risk D - Research funding (departmental or institutional). - MSD : Neither- audit of risk factor control - Pfizer : On-line guideline learning tool
Halcox Julian	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : Cardiovascular Pharmacology - Abbott : CV Pharmacology - Astra Zeneca : CV Pharmacology - Boehringer-Ingelheim : CV Pharmacology - Servier : CV Pharmacology - Roche : CV Pharmacology - Sanofi Aventis : CV Pharmacology - Merck Sharp & Dohme : CV Pharmacology
Hobbs Richard	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Hypertension - Astra Zeneca : Lipids, CV risk, Heart Failure - Pfizer : Lipids, CV risk, Thrombosis, Heart Failure - MSD-SP, Boehringer Ingelheim, Bayer : Lipids, Diabetes - Bayer : Thrombosis - Boehringer-Ingelheim : Thrombosis
Kjekshus John	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Transplantation - Schering-Plough : Vytorin

## ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - TF Members and Additional Contributors

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Kjekshus John	Yes	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Ivabradin
Perrone-Filardi Pasquale	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Takeda : candesartan - Boheringer : dabigatran - Merck, Schering Plough : ezitimibe - Menarini : ranolazine - Astra zeneca : rosuvastatin  E - Research funding (personal). - As a member of the TIMI Study Group I declare that our research group receives funding from a number of companies where I am not the PI. These include: Merck, BMS, Millennium, Nuvelo, Astra Zeneca, CV Therapeutics, Inotek, Schering-Plough, Integrated Ther : rivaroxaban, TIMI 50
Reiner Zeljko	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer Healthcare : anticoagulants - Astra Zeneca : antilipemics - Pfizer : antilipemics - Merck Sharp & Dohme : antilipemics - Abbott - lecture fees : antilipemics
Riccardi Gabriele	Yes	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Barilla : foods - Eli Lilly : insulin  D - Research funding (departmental or institutional). - Merck Sharp & Dohme : ezetimibe - Novo Nordisk : insulin
Storey Robert Frederick	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - The Medicines Company : Cangrelor - Sanofi Aventis : Clopidogrel

## ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - TF Members and Additional Contributors

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Storey Robert Frederick	Yes	<ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Clopidogrel</li> <li>- Novartis : Elinogrel</li> <li>- GlaxoSmithKline : Fondaparinux</li> <li>- Eli Lilly Lilly/Daiichi Sankyo - speakers fees; advisory board fees (prasugrel) : Prasugrel</li> <li>- Astra Zeneca : Ticagrelor</li> <li>- Merck : Vorapaxar</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Ticagrelor</li> <li>- Accumetrics : VerifyNow</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Prasugrel</li> <li>- Eli Lilly : Prasugrel</li> <li>- Astra Zeneca : Ticagrelor</li> <li>- Merck : Vorapaxar</li> </ul>
Taskinen Marja-Riitta	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Roche Pharma, advisory board : CETP inhibitor</li> <li>- MSD - speaker fee : CETP inhibitor, tredaptive</li> <li>- Boehringer Ingelheim - consulting or lecture fees : DDP4 inhibitor</li> <li>- Kowa, consulting or lecture fees : Statins</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- MSD : CETP inhibitor</li> <li>- Takeda : DDP4 inhibitor</li> <li>- Eli Lilly : Exenatide</li> <li>- Novo Nordisk : No product</li> </ul>
Wiklund Olov	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer - consulting or lecture fees : Atorvastatin</li> <li>- Merck - speaker fees : Ezetrol</li> </ul>

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Wiklund Olov	Yes	<ul style="list-style-type: none"> <li>- Astra Zeneca : Rousavstatin</li> <li>D - Research funding (departmental or institutional).</li> <li>- Sanofi Aventis : Antidiabetics basal studies</li> <li>- Pfizer : Atorvastatin</li> <li>- Gambro : Dialysis equipment</li> <li>- Ethicon Endo Surgery GmbH : Endosurgical equipment</li> <li>- PPD Scand AB/Takeda : Glithazon clinical study</li> <li>- Biogaia : Probiotics in metabolism</li> <li>- AstraZeneca : Rousuvastatin, and basal cardiovascular research</li> </ul>
Wood David Allan	Yes	<ul style="list-style-type: none"> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</li> <li>- Roche : Rheumatoid arthritis; Aleglitazar</li> <li>- Bayer Schering Pharma : 3rd ESC Asia CVD Symposium</li> <li>- Astra Zeneca : Crestor - Lipid Modification</li> <li>- Zentiva : Generic Drug Manufacturer</li> <li>- Merck Sharp &amp; Dohme : Niacin - Lipid Modification</li> <li>- Chugai Pharma UK : Rheumatoid Arthritis</li> <li>- Pfizer : Vernicline - Smoking Cessation</li> <li>D - Research funding (departmental or institutional).</li> <li>- Pfizer : Varenicline - Smoking Cessation</li> </ul>

## ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - Document Reviewers

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Berkenboom Guy	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Eli Lilly : antithrombotics</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra zeneca : statins</p>
Descamps Olivier	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Crestor - Merck Sharp &amp; Dohme : Inegy, Ezetrol, Zocor</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Crestor</p> <p>D - Research funding (departmental or institutional). - Astra Zeneca : crestor</p>
Funck-Brentano Christian	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pierre-Fabre : Cardiac Safety of non-cardiovascular products - Servier : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. - Johnson &amp; Johnson : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. - Sigma-Tau (Italy) : Cardiac Safety of an antimalarial drug - MMV (CH) : Cardiac Safety of an antimalarial drug - Santhera (CH) : Cardiac Safety of an antimalarial drug - TROPHOS : DSMB for an investigational drug in Amyotrophic Lateral Sclerosis – Cardiac safety - CEPHALON : DSMB in an oncology phase IIb trial - Jansen-Cilag : Proton-pump inhibitors and drug interactions, including Clopidogrel</p> <p>D - Research funding (departmental or institutional). Jansen-Cilag : Proton-pump inhibitors and drug interactions with Clopidogrel</p>
Gotcheva Nina	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca - speaker fees : Atacand, Ticagrelor - Boehringer Ingelheim - : Dabigatran - Sanofi-Aventis : Dronedarone</p>

## ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - Document Reviewers

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Gotcheva Nina	Yes	<p>- As a member of the TIMI Study Group I declare that our research group receives funding from a number of companies where I am not the PI. These include: Merck, BMS, Millennium, Nuvelo, Astra Zeneca, CV Therapeutics, Inotek, Schering-Plough, Integrated Ther : Rivaroxaban</p> <p>- Astra Zeneca : Ticagrelor</p> <p>- Actavis : Trimetazidine</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <p>- As a member of the TIMI Study Group I declare that our research group receives funding from a number of companies where I am not the PI. These include: Merck, BMS, Millennium, Nuvelo, Astra Zeneca, CV Therapeutics, Inotek, Schering-Plough, Integrated Ther : Rivaroxaban</p>
Griffith Kathryne	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <p>- Boehringer-Ingelheim : Atrial fibrillation and BP</p> <p>- Takeda Pharmaceuticals : canesartan management of heart failure and CKD</p> <p>- Bristol Myers Squibb : hypertension and kidney disease</p> <p>- Merck Sharp &amp; Dohme : lipid management</p>
Guida Guido Francesco	No	
Gulec Hasan Sadi	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <p>- Pfizer : atorvastatin</p> <p>- Bayer : nifedipin</p> <p>- Astra Zeneca - speaker fees : rosuvastatin and candesartan</p> <p>- Glaxo Smith Kline : telmisartan</p> <p>- Boehringer Ingelheim - speaker fees : telmisartan</p> <p>- Menarini - speaker fees : zofenopril</p>
Henkin Yaakov	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <p>- Merck Sharp &amp; Dohme : Ezetimibe, Tredaptive</p> <p>- Pfizer : Lipitor</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <p>- Merck Sharp &amp; Dohme : IMPROVE-IT study</p>
Huber Kurt	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <p>- Pfizer - speakers fees : atorvastatin</p>

## ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - Document Reviewers

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Huber Kurt	Yes	<ul style="list-style-type: none"> <li>- The Medicines Company - speakers fees : bivalirudin; cangrelor</li> <li>- BRAHMS GmbH - speakers fees : coceptin assay</li> <li>- Boehringer Ingelheim - speakers fees; advisory board fees (dabigatran) : dabigatran</li> <li>- Boston Scientific - speakers fees : none</li> <li>- Biotronik - speakers fees : none</li> <li>- Eli Lilly Lilly/Daiichi Sankyo - speakers fees; advisory board fees (prasugrel) : prasugrel; abciximab</li> <li>- Bayer - speaker fees; advisory board fees (rivaroxaban) : rivaroxaban</li> <li>- Astra Zeneca - speakers fees; advisory board fees (ticagrelor) : ticagrelor; rosuvastatin</li> </ul>
Kesaniemi Antero	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - MSD : Hypolipidemic therapy</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Schering-Plough : Hypolipidemic therapy</p> <p>D - Research funding (departmental or institutional). - Merck Schering Plough : Hypolipidemic therapy</p>
Lekakis John	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GSK : Darapladib - MSD : Vorapaxar</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GSK : Darapladib</p>
Manolis Athanasios John	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier, Menarini, Abbot, Recordati, Omron, Bayer, GSK, : Hypertension, CHD,AF,CHF</p>
Marques-Vidal Pedro	Yes	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Swiss Federal Office of Public Health : Consultant for National Nutritional Survey</p>
Masana Luis	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Esteve : Lipids - MSD : Lipids - Danone : lipids</p>



## ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - Document Reviewers

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Masana Luis	Yes	- Kowa : lipids
McMurray John	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis - consulting or lecture fees : NAVIGATOR/ASPIRE/ALTITUDE/PARADIGM-HF/VIVID studies</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis - consulting or lecture fees : Lixisenatide CV study</p> <p>C - Receipt of royalties for intellectual property. - Bristol Myers Squibb : ARISTOTLE study</p> <p>D - Research funding (departmental or institutional). - Amgen Inc : RED-HF/TREAT studies</p> <p>E - Research funding (personal). - F. Hoffman La Roche Ltd : ALECARDIO DSMS - Pfizer - consulting or lecture fees : EMPHASIS study - Glaxo Smith Kline : TIDE study</p>
Mendes Miguel Filipe	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - SanofiAventis : Dronedarone</p>
Pagava Zurab	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Les Lab. Servier in Georgia : Speaker fees - Novartis Pharma Services Group in Georgia : Speaker fees - Berlin-Chemie/MENARINI in Georgia : Speaker fees</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Confidential : Investigator</p>
Pedersen Terje	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Merck Sharp &amp; Dohme - speaker fees : Lipids</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca - speaker fee : Lipids</p> <p>C - Receipt of royalties for intellectual property. - Pfizer - speakers fees : Lipids</p>
Poldermans Don	Yes	<p>D - Research funding (departmental or institutional). - Maquette : Balloon pump device</p>

## ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - Document Reviewers

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Poldermans Don	Yes	<ul style="list-style-type: none"> <li>- Merck : drugs</li> <li>- Novartis : drugs</li> <li>- Baxter : drugs</li> <li>- Medtronic : Reveal device</li> </ul>
Prescott Eva	No	
Rato Quiteria A Mateus	No	
Rosano Giuseppe M C	No	
Sans Menendez Susana	No	
Stalenhoef Anton	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Genzyme, Shire HGT : cholesterol lowering</li> <li>- Merck Sharp &amp; Dohme : cholesterol lowering</li> </ul>
Tokgozoglulale	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Kowa : dyslipidemia</li> <li>- Abbott - lecture fees : dyslipidemia</li> <li>- Astra Zeneca, Bayer AG, Boehringer-Ingelheim, Daiichi-Sankyo, MSD, Novartis, Pfizer, Sanofi-Aventis, Servier : dyslipidemia, hypertension, antiplatelet, pulmonary hypertension</li> <li>- Servier : hypertension</li> <li>- Actelion - speaker fee : pulmonary hypertension</li> </ul>
Viigimaa Margus	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Coagulation</li> <li>- Glaxo Smith Kline : Coagulation</li> <li>- Servier : Coronary heart disease</li> <li>- Merck Sharp &amp; Dome : Dyslipidemia</li> <li>- Menarini : Hypertension</li> <li>- Boehringer Ingelheim : Hypertension</li> </ul>
Wittekoek Janneke	No	

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Zamorano Gomez Jose Luis	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Daiichi Sankyo : Anticoagulation - Philips : Imaging - Merck : Lipids
De Graaf Jacqueline	No	



## ESC Committee for Practice Guidelines 2010-2012

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Auricchio Angelo	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Biologics Delivery Systems, Cordis Corporation a Johnson &amp; Johnson company : Biological Therapy</li> <li>- Philips : Cardiac Imaging</li> <li>- Merck : Drugs</li> <li>- Biotronik : Implantable Cardiac Electronic Device</li> <li>- EBR Systems : Implantable Cardiac Electronic Device</li> <li>- Impulse Dynamics : Implantable Cardiac Electronic Device</li> <li>- Medtronic : Implantable Cardiac Electronic Device</li> <li>- Sorin : Implantable Cardiac Electronic Device</li> <li>- St. Jude Medical : Implantable Cardiac Electronic Device</li> <li>- Abbott : Implantable Cardiac Electronic Device</li> </ul>
Baumgartner Helmut	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease</li> <li>- AGA : Devices for catheter treatment of congenital heart defects</li> </ul>
Baumgartner Helmut	Yes	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Edwards Lifesciences : transcatheter valve implantation</li> </ul>
Bax Jeroen	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Heart.org : Education</li> <li>- Servier : Farma</li> <li>- Astra Zeneca : Farma</li> <li>- GE Healthcare : Imaging</li> <li>- Lantheus : Imaging</li> <li>- Philips : Imaging</li> <li>- St Jude Medical : Pacing</li> </ul>



## ESC Committee for Practice Guidelines 2010-2012

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Bax Jeroen	Yes	<ul style="list-style-type: none"> <li>- Medtronic : Pacing</li> <li>- Impulse Dynamics : Pacing</li> <li>- Biotronik : Pacing</li> <li>- Boston Scientific : Pacing</li> </ul> D - Research funding (departmental or institutional). <ul style="list-style-type: none"> <li>- Servier : Farma</li> <li>- Edwards Lifesciences : Heart Valves</li> <li>- Lantheus : Imaging</li> <li>- GE Healthcare : Imaging</li> <li>- Boston Scientific : Pacing</li> <li>- Medtronic : Pacing</li> <li>- St Jude Medical : Pacing</li> <li>- Biotronik : Pacing</li> </ul>
Ceconi Claudio	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Pharmaceutical
Deaton M Christi	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - St Jude Ltd : Cath lab - speaker X 1 - Daiichi Sankyo : consultant for patient adherence 2009-10 - Eli Lilly : consultant for patient adherence 2009-10
Deaton M Christi	Yes	D - Research funding (departmental or institutional). - Novo Nordisk : medicines for diabetes
Fagard Robert	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : perindopril; support for organisation of scientific meeting
Funk-Brentano Christian	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pierre-Fabre : Cardiac Safety of non-cardiovascular products



## ESC Committee for Practice Guidelines 2010-2012

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Funck-Brentano Christian	Yes	<ul style="list-style-type: none"> <li>- Servier : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials.</li> <li>- Johnson &amp; Johnson : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials.</li> <li>- Sigma-Tau (Italy) : Cardiac Safety of an antimalarial drug</li> <li>- Santhera (CH) : Cardiac Safety of an antimalarial drug</li> <li>- MMV (CH) : Cardiac Safety of an antimalarial drug</li> <li>- TROPHOS : DSMB for an investigational drug in Amyotrophic Lateral Sclerosis – Cardiac safety</li> <li>- CEPHALON : DSMB in an oncology phase IIb trial</li> <li>- Jansen-Cilag : Proton-pump inhibitors and drug interactions, including Clopidogrel</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Jansen-Cilag : Proton-pump inhibitors and drug interactions with Clopidogrel</li> </ul>
Hasdai David	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Enoxaparin</li> </ul>
Hoes Arno	Yes	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : unrestricted grant for diagnostic kits in suspected cardiovascular disease</li> <li>- Abbott Laboratories : unrestricted grant for diagnostic kits in suspected cardiovascular disease</li> <li>- Roche : unrestricted grant for diagnostic kits in suspected heart failure and acute coronary syndrome</li> </ul>
Knuuti Juhani	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Lantheus Inc : Imaging tracers</li> </ul>
Knuuti Juhani	Yes	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Bayer : Development of imaging agents</li> <li>- GE Healthcare : Development of imaging agents</li> <li>- Lantheus : Development of imaging agents</li> <li>- Novartis : Development of imaging agents</li> <li>- Roche : Drugs for brain diseases</li> </ul>
Kolh Philippe H	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p>



## ESC Committee for Practice Guidelines 2010-2012

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Kolh Philippe H	Yes	<ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Antiarrhythmic agents</li> <li>- Bristol Myers Squibb : Antiplatelet agents</li> <li>- Astra Zeneca : Antiplatelet agents</li> <li>- Regado Biosciences : Antithrombotic agents</li> <li>- Abbott - lecture fees : coronary stents</li> </ul> B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
Kolh Philippe H	Yes	D - Research funding (departmental or institutional). <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Cardiac valves</li> <li>- Medtronic : Cardiac valves</li> <li>- St Jude Medical : Cardiac valves</li> <li>- Siemens Healthcare : Imaging</li> <li>- Johnson &amp; Johnson : Thoracoscopic devices</li> </ul>
McDonagh Theresa	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Vifor International : Ferrinject</li> </ul>
McDonagh Theresa	Yes	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Servier - speaker fee : Ivabridine</li> </ul>
McDonagh Theresa	Yes	D - Research funding (departmental or institutional). <ul style="list-style-type: none"> <li>- Biotronik - Clinical Trial : CRT</li> </ul>
Poldermans Don	Yes	D - Research funding (departmental or institutional). <ul style="list-style-type: none"> <li>- Maquette : Balloon pump device</li> <li>- Merck : drugs</li> <li>- Novartis : drugs</li> <li>- Baxter : drugs</li> <li>- Medtronic : Reveal device</li> </ul>



## ESC Committee for Practice Guidelines 2010-2012

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Popescu Bogdan Alexandru	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GE Healthcare : Imaging
Reiner Zeljko	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer Healthcare : anticoagulants - Abbott - lecture fees : antilipemics - Astra Zeneca : antilipemics - Merck Sharp & Dohme : antilipemics - Pfizer : antilipemics
Sechtem Udo	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer Ingelheim : Anticoagulation - Daiichi Sankyo : Antiplatelet therapy - Novartis : Drugs - General Electric : Imaging - Siemens Healthcare : Imaging
Sechtem Udo	Yes	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Imaging devices - Johnson & Johnson : Stents
Simes Per Anton	Yes	D - Research funding (departmental or institutional). - Bayer : clinical studies atrial fibrillation investigator fee - Johnson & Johnson : investigator fee, clinical study, atrial fibrillation - MSD : investigator fee clinical studies hyperlipidemia, SCAD - Glaxo Smith Kline : investigator fee, clinical study , SCAD - Servier : investigator fee, clinical study, coronary artery disease - Jansen-Cilag : investigator fee, clinical study, diabetes CVD - Boehringer Ingelheim : investigator fee, clinical study, AF





## ESC Committee for Practice Guidelines 2010-2012

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Torbicki Adam	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : anticoagulation</li> <li>- Sanofi Aventis : anticoagulation</li> <li>- Pfizer : anticoagulation, pulmonary hypertension</li> <li>- Lilly : pulmonary hypertension</li> <li>- Actelion : pulmonary hypertension</li> <li>- Bayer Healthcare : pulmonary hypertension, anticoagulation</li> </ul>
Vahanian Alec	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Boehringer Ingelheim : Valve prostheses</li> <li>- Siemens Healthcare : Valve prostheses</li> <li>- Valtech : Valve prostheses</li> <li>- Edwards Lifesciences : Valve prostheses</li> <li>- Abbott : Valve prostheses</li> <li>- Medtronic - Advisory Board : Valve prostheses</li> </ul>
Windecker Stephan	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet drug</li> <li>- Eli Lilly : Antiplatelet drug</li> <li>- Abbott : Stent</li> <li>- Biosensors : Stent</li> <li>- Biotronik : Stent</li> <li>- Boston Scientific : Stent</li> <li>- Cordis : Stent</li> <li>- Medtronic : Stent</li> </ul>
Windecker Stephan	Yes	D - Research funding (departmental or institutional). <ul style="list-style-type: none"> <li>- Medtronic : Stent</li> </ul>



EUROPEAN  
SOCIETY OF  
CARDIOLOGY®

## ESC Committee for Practice Guidelines 2010-2012

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
		- Abbott : Stent - Biosensors : Stent - Cordis : Stent

This table represents the relevant relationships of the above experts with Industry and other entities that were reported to us at the time of publication of the guidelines.